The transcription factor FleQ is a bacterial AAA+ ATPase enhancerbinding protein that is the master activator of flagella gene expression in the opportunistic bacterial pathogen Pseudomonas aeruginosa. Homologs of FleQ are present in all Pseudomonas species and in many polarly flagellated gamma proteobacteria. Cyclic diguanosine monophosphate (c-di-GMP) is a second messenger that controls the transition between planktonic and biofilm modes of growth in bacteria in response to diverse environmental signals. C-di-GMP binds to FleQ to dampen its activity, causing down-regulation of flagella gene expression. This action is potentiated in the simultaneous presence of another protein, FleN. We explored the effect of c-di-GMP and FleN on the ATPase activity of FleQ and found that a relatively low concentration of c-di-GMP competitively inhibited FleQ ATPase activity, suggesting that c-di-GMP competes with ATP for binding to the Walker A motif of FleQ. Confirming this, a FleQ Walker A motif mutant failed to bind c-di-GMP. FleN, whose gene is regulated by FleQ, also inhibited FleQ ATPase activity, and FleQ ATPase activity was much more inhibited by c-di-GMP in the presence of FleN than in its absence. These results indicate that FleN and c-di-GMP cooperate to inhibit FleQ activity and, by extension, flagella synthesis in P. aeruginosa. The Walker A motif of FleQ is perfectly conserved, opening up the possibility that other AAA+ ATPases may respond to c-di-GMP.
B
is-(3′-5′)-cyclic diguanosine monophosphate (c-di-GMP) is an ubiquitous second messenger in bacteria, where it affects the transition between a motile planktonic lifestyle and an adhesive biofilm lifestyle by binding to various effector proteins to modulate enzymatic activity, protein-protein interactions, transcription, and translation (1) (2) (3) (4) (5) (6) . One of these effector proteins is FleQ (PA1097), an enhancer-binding protein (EBP) transcription factor from the opportunistic pathogen Pseudomonas aeruginosa.
FleQ contains an N-terminal FleQ domain, a central AAA+ ATPase domain, and a C-terminal helix-turn-helix DNA-binding domain. It activates expression of biofilm-related genes, including genes for Pel and Psl exopolysaccharide (EPS) in response to binding of c-di-GMP at an unknown site (7, 8) . EBPs typically act in conjunction with σ 54 -RNA polymerase; however, FleQ regulates EPS gene expression independent of σ 54 , most likely with σ 70 (8, 9 ). In addition to regulating genes for biofilm formation, FleQ has a second, better-known role as a σ 54 -dependent master regulator of P. aeruginosa flagella gene expression (9, 10) . FleQ activates expression of the two-component regulatory genes fleSR, as well as genes for the assembly of the flagella export apparatus and for the initiation of flagella basal body assembly. FleSR controls genes to complete the basal body-hook structure (9, 11) .
The regulation of both flagella and biofilm genes is also under the control of a second protein, FleN. Mutations in fleN (PA1454) lead to an up-regulation of flagella gene expression and a smalldown-regulation of biofilm genes (7, 12) . The expression of fleN is under the control of FleQ. FleN is a putative ATPase containing a deviant Walker A motif (13) . FleN and FleQ interact with one another in the presence as well as in the absence of ATP or c-di-GMP, and a FleQ/FleN complex binds to pel, fleSR, and flhA promoter DNA (7, 8, 14) .
Transcriptome studies have shown that the expression of most FleQ-controlled flagella genes is down-regulated by 1.5-to 2-fold when intracellular c-di-GMP is high (7, 15) . To investigate the basis for this effect, we tested the influence of c-di-GMP on FleQ ATPase activity. In general, ATP hydrolysis by EBPs like FleQ provides energy for remodeling the σ 54 -RNA polymerase closed complex, allowing loading of the template strand of DNA into the active site of the RNA polymerase (16, 17) . Energy is transferred by direct interaction of σ 54 and the EBP. Our results indicate that FleQ has a strong cooperative ATPase activity, and that FleN and c-di-GMP inhibit FleQ ATPase activity, thereby explaining their effects in depressing the ability of FleQ to activate flagella gene expression. Our results further suggest that an intact Walker A motif is necessary for the binding of c-di-GMP to FleQ.
Results
FleQ Exhibits Cooperative ATPase Activity. In initial experiments, we found that the ATPase activity of FleQ did not obey classical Michaelis-Menten kinetic relationships (Fig. 1A) . Indeed, the enzyme kinetic curves were sigmoidal instead of hyperbolic. The Hill coefficient for ATPase activity of FleQ was approximately 2.5 (Table 1) , implying a strong positive cooperativity in sequential binding and hydrolysis of ATP. FleQ ATPase activity was not subject to product inhibition or stimulation (Fig. 1B , FleQ + ADP), and time course experiments showed that FleQ ATPase activity was linear at different ATP concentrations, suggesting that no substrate inhibition occurred at high ATP concentrations. FleQ ATPase activities in the presence or absence of a DNA fragment encompassing the FleQ-binding site of the
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fleSR promoter (7) were similar, suggesting that FleQ has DNAindependent ATPase activity (Fig. 1B) . FleQ has a N-terminal domain of unknown function, known as the FleQ domain. FleQ truncated of this domain had threefold lower ATPase activity relative to full-length FleQ, suggesting that the FleQ domain may positively regulate the activity of the AAA+ domain (Fig. 1B) .
The ATPase activity of EBPs is strongly influenced by their ability to form high-order oligomers (18) . EBPs are typically dimeric in their inactive state and must form a higher-order oligomer (mostly hexamers) for high rates of ATP hydrolysis to occur. In most cases, the formation of these active hexamers requires ATP binding, but ligand binding, phosphorylation, or binding to DNA also can influence EBP oligomerization (17) . We assessed the oligomeric state of FleQ by running purified protein on a blue native (BN) gel. FleQ dimers were the primary forms detected, but FleQ tetramers and some FleQ hexamers were observed as well (Fig. 2) .
The finding that FleQ forms oligomers is consistent with the cooperative ATPase activity of the enzyme. However, preincubation of FleQ with ATP, ADP, AMP, ATPγS, c-di-GMP, or GTP did not change the oligomeric state of FleQ, as is generally the case for EBPs. To detect possible transient associations, we also performed BN-PAGE in the presence of ATP in the buffer, but found no differences. FleQ dimers, isolated by size-exclusion chromatography, had the same ATPase-specific activity as unfractionated FleQ. FleQ dimers also showed a cooperative ATPase activity, with a Hill coefficient of 2.53 ± 0.03.
AAA+ ATPase domains are characterized by Walker A and Walker B motifs, which are involved in nucleotide binding and hydrolysis, respectively (16, 17) . The Walker A motif forms a P-loop with the consensus sequence GxxxxGK(T/S) and interacts with the phosphates of ATP. In the Escherichia coli protein PspF, substitution of the lysine residue of the Walker A motif with an alanine (PspF K42A ) abolishes the binding and hydrolysis of ATP (19) . The Walker B motif has a consensus sequence of hhhhDE (where h is a hydrophobic amino acid), which may play a role in the coordination of Mg 2+ , which is necessary for ATP hydrolysis. PspF protein with D107S or E108Q substitutions in the Walker B motif exhibited decreased ATP hydrolysis but increased ATP binding (20) .
As expected, introduction of the corresponding mutations in the putative Walker A motif (FleQ K180A ) or Walker B motif (FleQ D245A and FleQ E246Q ) of FleQ drastically decreased ATPase activity, whereas replacement of the threonine of the σ 54 -binding domain with a serine (FleQ T224S ) had no effect (Fig.  1B) . Thus, the properties of the predicted Walker A and B motifs of FleQ are consistent with those of other EBPs.
FleN Exhibits Low ATPase Activity and Inhibits FleQ ATPase Activity.
FleN is a putative ATPase with a deviant Walker A motif (xxKGGxxK [T/S]) belonging to a functionally diverse group that includes MinD and ParA (13, 21) . These proteins have very low ATPase activity in common. The FleN ATPase activity was also low, and FleN ATPase activity decreased significantly when ATPγS was added as a competitive inhibitor (Fig. 3A) . Previously reported data indicate that FleN is a FleQ antiactivator. Flagella gene expression is high in an fleN background (12, 14) .
To test the hypothesis that FleN inhibits FleQ ATPase activity, we measured the total ATPase activity of a fixed concentration of FleQ (1 μM) incubated with increasing concentrations of 
No c-di-GMP 320 ± 10.6 0.68 ± 0.03 2.6 ± 0.3 c-di-GMP 25 μM 3 0 0± 7.6 0.98 ± 0.02 3.2 ± 0.3 c-di-GMP 37.5 μM 2 8 0± 9.7 1.17 ± 0.04 3.6 ± 0.4 c-di-GMP 50 μM 2 8 0± 23 1.50 ± 0.13 2.9 ± 0.5
Hill coefficient ± SD. . Thus, we wondered whether c-di-GMP might inhibit FleQ ATPase activity. Testing this possibility revealed that FleQ ATPase activity decreased with increasing c-di-GMP concentration (Fig. 4A) . Kinetic analyses showed that c-di-GMP raised the apparent K half (corresponding to the concentration of substrate that produces half-maximal enzyme velocity) values for ATP, but had almost no effect on the apparent V max values, indicating that c-di-GMP inhibits FleQ ATPase activity in a competitive manner ( Fig. 4B and Table 1 ).
An Intact Walker A Motif Is Required for Binding of c-di-GMP to FleQ.
Competitive inhibition of enzyme activity can be most readily explained by binding of substrate and inhibitor to the same site on an enzyme. To test this hypothesis, we purified and subjected to trypsin proteolysis FleQ variants containing amino acid substitutions in the Walker A motif (FleQ K180A ), the Walker B motif (FleQ D245A and FleQ E246Q ), and the σ 54 -binding domain (FleQ T224S ). We have previously reported that WT FleQ undergoes a conformational change on binding of c-di-GMP, which can be detected by a change in its trypsin digestion profile (8) . In the absence of c-di-GMP, a major proteolysis fragment of 20 kDa was detected after 30 min of incubation with trypsin, whereas in the presence of c-di-GMP, a different proteolysisresistant fragment of ∼30 kDa appeared (Fig. 5) . This ∼30-kDa fragment did not appear when FleQ K180A was subjected to trypsin digestion in the presence of c-di-GMP, suggesting that FleQ K180A does not bind c-di-GMP. In comparison, FleQ D245A , FleQ E246Q , and FleQ T224S had the same trypsin digestion profiles as the WT FleQ when incubated with c-di-GMP, indicating that they are able to bind c-di-GMP.
We performed isothermal titration calorimetry (ITC) to further confirm that FleQ K180A does not bind c-di-GMP. We found that WT FleQ bound c-di-GMP with a K d of 7 μM (Fig. 6) , comparable to the 15 μM reported by Hickman and Harwood (Fig.  7) . The ATPase activity of FleQ alone was inhibited by c-di-GMP with an IC 50 value of 67.5 μM (SE, logIC 50 of 0.06). This value fell to 9 μM (SE, logIC 50 of 0.03) when FleN was present. FleN ATPase activity was not affected by the presence of c-di-GMP. This indicates that inhibition of FleQ ATPase activity by c-di-GMP is enhanced by FleN, and suggests that FleQ and FleN cooperate to detect c-di-GMP.
Discussion
Here we have presented two lines of evidence suggesting that the Walker A motif of the AAA+ domain of FleQ is involved in the binding of c-di-GMP. We have shown that c-di-GMP competitively inhibits FleQ ATPase activity, with c-di-GMP having a much higher affinity for FleQ compared with ATP (Fig. 4) , and that a Walker A mutant of FleQ failed to bind c-di-GMP (Figs. 5 and 6). The most straightforward interpretation of these results Table 1 ).
is that c-di-GMP binds to the Walker A motif of FleQ; however, in the absence of structural data, we cannot exclude the possibility that c-di-GMP binds elsewhere on FleQ to influence its ATPase activity, and that an intact Walker A motif is required for binding at this alternative site.
The effects of c-di-GMP and FleN on inhibition of FleQ ATPase activity explain their effects on repression of flagella gene expression in vivo. In the absence of c-di-GMP and FleN, FleQ exhibits full ATPase activity (Fig. 1) . As with other EBPs, we propose that the hydrolysis of ATP by FleQ remodels σ 54 -RNA polymerase closed complexes, resulting in the formation of open promoter complexes competent for transcription. Flagella genes under the control of FleQ, including the fleN gene, are expressed (9) . The FleN protein interacts with FleQ bound to flagella gene promoters (7, 14) and inhibits FleQ ATPase activity (Fig. 3) . This leads to a σ 54 -RNA polymerase complex in a configuration that is less competent for transcription, resulting in the down-regulation of flagella gene expression such that WT cells synthesize a single polar flagellum.
After surface sensing (22) , or depending on the cell cycle (23) or other environmental signals (4, 24, 25) , the intracellular concentration of c-di-GMP can increase in P. aeruginosa cells. A recent study showed that the concentration of intracellular c-di-GMP in WT P. aeruginosa cells grown in liquid is approximately 11 μM, but can increase to >30 μM when diguanylate cyclase activity is high (26) . C-di-GMP levels can be very low in cells expressing phosphodiesterases (27) . C-di-GMP binds to FleQ (7) and further inhibits its ATPase activity (Figs. 4 and 7) , leading to further down-regulation of flagella gene expression. Moreover, c-di-GMP inhibition of FleQ ATPase activity is enhanced by the presence of FleN, suggesting that FleQ and FleN cooperate to detect c-di-GMP.
The fact that both FleN and c-di-GMP target the ATPase activity of FleQ and that FleQ with or without FleN is maintained bound to the flagella gene promoters in the presence as well as in the absence of c-di-GMP (7), suggests that this organization might be a biological advantage, allowing cells to rapidly respond to changing concentrations of c-di-GMP. Previously reported transcriptome data show only modest decreases in flagella gene expression in response to c-di-GMP (15, 27) ; however, the equilibrium among all of the components of the flagellum is so important that even a small reduction in gene expression may have a large impact.
FleQ has several features that make it an unusual EBP. Whereas typical EBPs form inactive dimers, which assemble as active hexamers on ATP binding, we found that FleQ forms mostly active dimers and detected few hexamers (Fig. 2) . The presence of FleQ dimers with ATPase activity may signify that (34) , and VpsR from V. cholerae, remain to be identified (35) . The X. campestris Clp protein and FleQ belong to well-conserved and well-studied families of transcriptional regulators. In the X. campestris Clp protein, one residue out of the six key residues known to be involved in the binding of cAMP is not conserved, and this particular residue turns out to be important for c-di-GMP binding. In contrast, the Walker A motif of FleQ is perfectly conserved, opening up the possibility that other AAA+ ATPases may bind and respond to c-di-GMP.
Materials and Methods
FleQ Mutant Construction and Protein Purification. Mutations in the fleQ gene were generated by an overlapping PCR procedure with two sets of divergent and complementary primers, each set containing the expected substitution and the convergent primers FleQ intein up and FleQ intein down previously used to amplify the fleQ gene (7). Primer sequences are available on request. The NdeI-EcoRI fragments thus produced were cloned into pTYB12, generating pFleQK180A-Int1, pFleQT224S-Int1, pFleQD245A-Int1, and pFleQE246Q-Int1. Plasmids were transformed into E. coli ER2566 for expression of fusion protein. FleQ and FleN were purified as described previously (7), and FleQ variants were purified following the same protocol as for WT FleQ. Truncated FleQ (FleQ-trunc) has been described previously (7) . The A260/A280 ratio of the purified FleQ proteins and BSA as control were similar, suggesting no contamination of purified protein by nucleotides.
The FleQ protein also was subjected to size-exclusion chromatography. Protein was injected into a Superdex 200 10/300 GL column (GE Healthcare). The buffer was composed of 25 mM Tris (pH 7.5), 100 mM NaCl, 1 mM DTT, and 2 mM MgCl 2 . Chosen fractions were directly assayed for their ATPase activity immediately after elution from the column.
Limited Proteolysis. Trypsin digestion was performed as described previously (8) . In brief, 8 μg of FleQ WT or variant protein was incubated with 8 μg of BSA and 500 μM c-di-GMP when necessary for 10 min, followed by the addition of 1.6 μg of trypsin. At prespecified intervals, reactions were stopped by plunging 11 μL of the proteolysis mix into cold SDS loading buffer. The samples were heated for 10 min at 95°C and then analyzed by SDS/PAGE, followed by transfer to nitrocellulose membrane for detection with antiFleQ antiserum.
ATPase Activity. ATPase activity was assayed by measuring the production of inorganic phosphate (Pi) using the Enzchek Phosphate Assay Kit (Invitrogen). The reactions were set up as specified by the manufacturer, except that the MgCl 2 concentration was increased to 2 mM and 10 mM KCl and 1 mM DTT were added. FleQ WT or variant protein and FleN were added to reaction mixtures as indicated, followed by incubation for 10 min at room temperature before ATP was added to start the reaction. When necessary, c-di-GMP (Axxora; >95% purity), 100 μM ADP, or 0.25 μM DNA fragment encompassing the fleS promoter (corresponding to a ratio of 125 pmol of DNA to 500 pmol of FleQ monomer) was incubated with FleQ with or without FleN for 10 min before the assay. The kinetics of Pi release were monitored by reading at OD 360 . A standard curve with KH 2 PO 4 as the source of inorganic phosphate was performed. The specific activity (nmol Pi/min/mg of FleQ) versus ATP concentration was used to determine kinetic parameters. These were calculated by the nonlinear regression/allosteric sigmoidal enzyme kinetics model (Hill equation) using GraphPad Prism 4.
In an alternative approach, enzyme velocity was measured at a single concentration of substrate with varying concentrations of a competitive inhibitor (c-di-GMP) to determine the IC 50 . IC 50 values were calculated using the nonlinear regression/sigmoid dose-response (variable slope) kinetics model with GraphPad Prism 4. The same data are presented in Figs. 1A and 4B. Each experiment was performed at least two times, and the maximum error observed was 12%.
Separation by BN-PAGE. In BN-PAGE, Coomassie G-250 binds to proteins and confers a net negative charge while maintaining the proteins in their native state. Purified FleQ proteins (50 μg) were mixed with 10 mM ATP, AMP, ADP, ATPγS, or GTP or 1 mM c-di-GMP in binding buffer containing 10 mM Tris (pH 8), 8 mM magnesium acetate, 50 mM KCl, and 5% glycerol for 10 min at room temperature. The samples were then loaded on a 4-16% Native-PAGE Novex Bis-Tris gel (Invitrogen) with dark-blue cathode buffer (0.02% Coomassie G-250), followed by electrophoresis for 2 h at 150 V and room temperature. NativeMarker Unstained (Invitrogen) served as a protein standard.
ITC. WT FleQ (29 μM), FleQ K180A (20 μM), and c-di-GMP (600 μM) were prepared in 25 mM Tris·HCl, 300 mM NaCl, and 5 mM MgCl 2 , and each solution was degassed before use in experiments. ITC measurements were performed with a MicroCal ITC-200 system (GE Healthcare). Except for the first injection, each titration experiment consisted of 37 1-μL injections with a 125-s interval between injections. The ITC data were analyzed with Origin v7.0 software (OriginLab) and fit using a single-site binding model.
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